XML 32 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Summary Of Significant Accounting Policies - (Tables)
6 Months Ended
Jun. 30, 2020
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payer and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2020201920202019
Janssen (SIMPONI®)
23 %*11 %*
Medicare18 %27 %22 %27 %
Blue Shield11 %12 %12 %13 %
United Healthcare*10 %*10 %
Medicare Advantage*11 %11 %11 %

 Accounts Receivable
 June 30, 2020December 31, 2019
 
Janssen (SIMPONI®)
28 %19 %
United Healthcare14 %22 %
Anthem Blue Cross Blue Shield12 %*
Blue Shield10 %15 %

*Less than 10%.
Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payer and customer category (in thousands):
 
 Three Months Ended June 30,Six Months Ended June 30,
 2020201920202019
Revenue:
Healthcare insurers$4,138  $6,067  $10,200  $11,528  
Government1,807  2,867  4,052  5,299  
Client746  1,088  1,828  2,193  
Other(1)206  148  401  310  
Janssen (SIMPONI®)
2,051  304  2,051  404  
Total revenue$8,948  $10,474  $18,532  $19,734  
(1)Includes patient self-pay that is immaterial.
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
 June 30, 2020December 31, 2019
 
Cash and cash equivalents$63,700  $72,084  
Restricted cash100  100  
$63,800  $72,184  
Schedule of Cash and Cash Equivalents
Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):
 
 June 30, 2020December 31, 2019
 
Cash and cash equivalents$63,700  $72,084  
Restricted cash100  100  
$63,800  $72,184  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):
 
 Three Months Ended June 30,Six Months Ended June 30,
 2020201920202019
Redeemable convertible preferred stock—  6,013,941  —  6,013,941  
Warrants to purchase redeemable convertible preferred stock—  224,493  —  224,493  
Warrants to purchase common stock426,827  934,789  426,827  934,789  
Common stock options1,677,000  662,987  1,677,000  662,987  
Total2,103,827  7,836,210  2,103,827  7,836,210